Opioids depress the activity of brainstem respiratory-related neurons but it is not resolved whether the mechanism at clinical concentrations consists of direct neuronal effects or network effects. We performed extracellular recordings of discharge activity of single respiratory neurons in the caudal ventral respiratory group of decerebrate dogs, which were premotor neurons with a likelihood of 90%. We used multibarrel glass microelectrodes, which allowed concomitant highly localized picoejection of opioid receptor agonists or antagonists onto the neuron. 
INTRODUCTION
Opioid agonists such as morphine, fentanyl and remifentanil are potent clinical analgesics and respiratory depressants. The respiratory depressant effects are thought to be mainly due to µ receptor activation although depression by δ opioid receptor activation has also been implicated (Sales et al. 1985) . Neurons expressing opioid receptors have been identified throughout the respiratory system. For example, μ and δ opioid receptors have been pharmacologically (Denavit-Saubie et al. 1978 ) (Morin-Surun et al. 1984) and immunohistochemically (Haji et al. 2003b ) identified on feline respiratory neurons, where they are differentially distributed either predominantly on the soma, e.g., in most bulbospinal premotor neurons, or on the dendrites (Haji et al. 2003b) . Several studies have shown that clinical (Haji et al. 2003a; Lalley 2003) and/or pharmacological (Denavit-Saubie et al. 1978; Lalley 2003; Morin-Surun et al. 1984) concentrations of fentanyl and morphine cause depression of various types of respiratory neurons in vivo via both direct and indirect mechanisms. However, it remains unresolved whether clinically relevant concentrations of opioids exert their effect via network effects or via direct effects on specific respiratory neurons in the brainstem.
We investigated this question for respiratory bulbospinal neurons in a decerebrate dog model that allows us to study the effects of synaptic neurotransmitters and pharmacological agonists or antagonists on functionally identified single respiratory 4 neurons in vivo under physiologically relevant conditions without confounding background anesthesia (Tonkovic-Capin et al. 1998 ). In this model, inspiratory and expiratory bulbospinal premotor neurons are the major source of excitatory drive (Dogas et al. 1995; Krolo et al. 1999; Krolo et al. 2000) for inspiratory and expiratory motoneurons, which directly activate the respiratory musculature and may thus be direct or indirect targets of clinical opioid effects.
As a first step we sought to determine whether µ and δ opioid receptors were present on canine respiratory premotor neurons. We investigated whether selective µ and δ opioid agonists had direct and reversible depressant effects on these neurons in vivo as well as the maximum effect for each agonist. Once the presence of functional opioid receptors was established, we investigated with similar protocols whether picoejection of the clinical µ opioid agonists morphine and remifentanil had a direct depressant effect on premotor neurons and whether the doses necessary to achieve neuronal depression were in a plasma concentration range that can be expected during clinical use. Morphine was chosen because of its frequent clinical use and to allow comparison of our model with multiple studies in other in vivo and in vitro preparations.
Remifentanil was chosen to allow direct comparison with the subsequent protocol using intravenous remifentanil. With the last protocol we investigated whether the significant depression of respiratory premotor neurons that is caused by clinical dose rates of intravenous remifentanil resulted at least in part from a direct opioid effect. We used the clinical µ opioid agonist remifentanil because the pharmacokinetics of this drug allowed achievement of a steady-state global respiratory depression with intravenous infusion and then a quick recovery to baseline conditions for post-remifentanil control runs. The 5 fast and complete metabolism of the drug also allowed multiple protocols in the same animal without confounding effects of residual systemic opioids.
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METHODS
This research was approved by the subcommittee on animal studies of the Zablocki VA Medical Center, Milwaukee, WI, in accordance with provisions of the Animal Welfare Act, the PHS Guide for the Care and Use of Laboratory Animals and VA policy. Experiments were performed on mongrel dogs of either sex, weighing from 8 to 16 kg. Inhalational anesthesia was induced by mask and maintained with isoflurane at 1.5-2.5% end-tidal concentration. The animals were monitored for signs of inadequate anesthesia such as salivation, lacrimation, and increases in blood pressure and heart rate. If required, anesthetic depth was increased immediately.
Surgical procedures
The trachea of dogs was intubated with a cuffed endotracheal tube and their lungs mechanically ventilated with an air-O 2 -isoflurane mixture. The surgical procedures, monitoring and maintenance of body homeostasis have been previously described in detail (Dogas et al. 1998) . Briefly, after cannulating the femoral artery for blood pressure recording and blood gas sampling and femoral vein for continuous infusion of maintenance fluids and administration of drugs, a bilateral pneumothorax was performed to reduce motion artifacts. The animal was then decerebrated by midcollicular transection (Tonkovic-Capin et al. 1998 ) and isoflurane was discontinued.
After decerebration the animal was ventilated with an air-O 2 mixture and maintained in hyperoxic normocapnia (FiO 2 >0.6). The dorsal surface of the medulla oblongata was exposed by an occipital craniotomy for neuronal recording. Phrenic nerve activity was recorded from the desheathed right C5 rootlet. The phrenic neurogram (PNG) was obtained from the moving-time average (100 ms) of the amplified phrenic nerve activity 7 and was used to produce timing pulses corresponding to the beginning and end of the inspiratory phase. Continuous neuromuscular block was achieved with pancuronium (0.1 mg/kg/h) to reduce motion artifacts during neuronal recordings.
Picoejection Technique and Neuronal Recording
A minimum of one hour was allowed for preparation stabilization before data collection. Extracellular single unit recordings from caudal ventral respiratory group (VRG) neurons were obtained using multibarrel micropipettes (10-30 μm composite tip diameter) consisting of a recording barrel containing a 7 μm thick carbon filament and three drug barrels. We have shown in previous studies that over 90% of antidromicallytested inspiratory (Bajic et al. 1992; Stuth et al. 1994 ) and expiratory (Bajic et al. 1992) neurons in the caudal and intermediate VRG from where we sampled neurons were bulbospinal premotor neurons. The microelectrodes allowed extracellular recordings of neuronal action potentials before and during pressure ejection of picomolar amounts of opioid agonists or the opioid antagonist naloxone onto the neuron. The ejected solutions consisted of artificial cerebrospinal fluid (aCSF) and one of the following agents that was dissolved in aCSF at a 1 mM concentration: the μ receptor agonist [D- MgCl, 1.3 KH 2 PO 4 , 0.9 CaCL 2 , 26 NaHCO 3 , and 11 glucose. Similarly, the µ receptor agonist morphine sulfate was dissolved in aCSF in concentrations of 10 µM, 100 µM and 1mM, and the µ agonist remifentanil was dissolved in aCSF in concentrations of 240 nM and 480 nM. Since remifentanil was only available from one source, the final 8 solutions also contained 10 and 20 µM glycine. The picoejected dose-rate was measured via height changes of the meniscus in the pipette barrel with a x 50 magnification microscope equipped with a reticule (resolution ~ 2 nl). The picoejection technique has been described in detail by Dogas et al.(1998) and Krolo et al.(1999) .
The location of the recorded neurons was in a region extending from 1 -5 mm caudal to the obex, 2.5 -4.5 mm lateral to the midline and 2 -4.5 mm below the dorsal medullary surface. A distance of at least 500 µm was required between picoejection sites to ensure that results were not confounded by residual drug effects (<0.3% of barrel concentration for a 10 nl injection, Nicholson 1985) . A time-amplitude window discriminator was used to generate a standard logic pulse for each spike. Neuronal discharge frequency, F n , was continuously determined by the number of discharges in each 100 msec time increment.
Protocols
1.
Picoejection of subtype specific opioid receptor agonists onto single neurons: determination of the presence of opioid receptor subtypes and maximum effect
After establishing a stable recording of single neuron activity, the neuronal control activity was recorded for at least 2-4 min. Then picoejection was started and the dose-rate was gradually increased until a neuronal response was observed. Thereafter the dose rates were increased stepwise until the effects saturated, i.e., an additional increase in dose-rate did not produce any further change in neuronal activity. To avoid potential cross contamination from multiple barrels only one selective agonist was 9 tested for each neuron protocol. In a subset of neurons, after maximal effects had been obtained, picoejection of the nonselective opioid antagonist naloxone was used to ensure that the agonist effects were reversible. In a separate group of neurons this antagonist was picoejected without prior agonist application to determine whether the neurons received any endogenous input through opioid receptors.
2.
Picoejection of morphine onto single neurons: assessment of the threshold concentration for a direct morphine effect and of the maximum direct morphine effect
In a second set of animals, the prototypic clinical µ agonist morphine was picoejected in increasing dose rates until a ceiling effect was reached for each of the three concentrations tested. Since the experimental setup has a limit of three drug barrels we initially tested only the higher morphine concentrations (100 µM and 1 mM).
When we found that the 100 µM concentration already led to a significant neuronal depression we added experiments with 10 µM morphine to more closely assess the threshold concentration for neuronal depression. In a subset of neurons, reversibility of the morphine effect was tested with naloxone. In addition, i.e., at least once per animal, picoejection of the aCSF vehicle was used to verify that the aCSF constituents and ejected volumes were without effect on single neurons.
3.
Picoejection of remifentanil onto single neurons: assessment of a direct depressant effect of clinically relevant concentrations
In a third set of animals, the clinical µ agonist remifentanil was picoejected in increasing dose rates until a ceiling effect was reached for each of the two concentrations tested. Since remifentanil is only commercially available as a mixture with glycine we only tested two concentrations of remifentanil (240 nM and 480 nM).
These concentrations are about 10 to 20 times higher than published peak plasma concentrations encountered clinically during high-dose intravenous remifentanil infusions. The final glycine concentrations in the picoejected solution were 10 and 20 μM, which is below the effective concentration for in vivo picoejection (0.5 -1 mM, unpublished observations from glycine picoejection experiments, EJ Zuperku, Milwaukee, WI, 5/03-2/04). In a subset of neurons, reversibility of the remifentanil effect was tested with naloxone. In addition, i.e., at least once per animal, picoejection of the aCSF vehicle was used to verify that the aCSF constituents and ejected volumes were without effect on neuronal frequency.
4.
Picoejection of the opioid antagonist naloxone onto single neurons during intravenous remifentanil infusion: does direct opioid receptor activation on premotor neurons contribute to the respiratory depression by systemic remifentanil In this protocol a stable recording from a single respiratory bulbospinal neuron was obtained and baseline activity was recorded. Then an intravenous infusion of the µ agonist remifentanil was started and increased until peak phrenic nerve activity was depressed by ≈ 50%. The required doses (0.2-0.6 µg/kg/min) were in the clinically used dose range for dogs, which is similar to humans. Once a steady state depression of 11 peak phrenic activity and neuronal discharge frequency was established for at least 5 minutes, the nonselective opioid antagonist naloxone was picoejected onto the neuron in increasing dose rates. Dose rates were chosen that had previously completely reversed the depressant effect of 1 mM DAMGO picoejected onto a different premotor neuron in the same animal. Any reversal of the remifentanil induced neuronal depression by local naloxone was considered evidence of direct postsynaptic neuronal depression of the neuron. In addition, to assess any endogenous activation of neuronal opioid receptors, which may confound the determination of direct remifentanil effect, naloxone was again ejected onto the same neuron after remifentanil was stopped and neuronal and phrenic nerve activity had recovered to control levels.
Data analysis
Cycle-triggered histograms (CTHs; bin width: 50 ms), triggered from the onset of either the inspiratory or expiratory phase as defined by the phrenic neurogram, and based on 5-20 respiratory cycles were used to quantify the neuronal discharge pattern, peak F n and time-averaged F n during the active neuronal phase. Peak F n correlates closely with the peak excitatory drive transmitted to the phrenic motoneurons while the average F n allows a better interpretation of the drug effects on the overall neuronal discharge pattern (Eldridge 1975) . For peak and average F n , the values obtained during the pre-ejection control period were used to normalize the values during the maximum effect of the respective drug. The main a priori goals of these studies were to determine the maximum drug effect for each agonist and to determine whether there were differential effects between inspiratory and expiratory neurons. For protocol 4, the effects of intravenous remifentanil and local naloxone antagonism on peak F n were analyzed using a Two-Way Repeated Measures ANOVA (One Factor Repetition) with type of neuron and type of treatment (e.g., remifentanil/naloxone) as main factors. Differences were considered significant for p<0.05. Values are expressed as means ± SE.
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RESULTS
1.
Picoejection of subtype specific opioid receptor agonists onto single neurons: determination of the presence of opioid receptor subtypes and maximum effect 15 animals were used for this protocol. A representative example of the response to picoejection of increasing dose rates of the selective µ agonist DAMGO (1 mM) is shown in figure 1 for an inspiratory premotor neuron. The inspiratory neuronal peak discharge frequency F n was depressed from 75 to 50 Hz at maximally effective dose-rates of DAMGO of 67 pmol/min. Examples of the cycle-triggered histograms (CTHs) of inspiratory and expiratory neuronal responses to DAMGO, DPDPE, deltorphin II and naloxone are shown in figure 2A and 2B, respectively. Figure 2A shows that all three agonists depressed the peak discharge frequency of three different inspiratory neurons at maximally effective dose-rates. Naloxone fully reversed these effects. Figure 2B suggests that only DAMGO and deltorphin II are more depressant than the δ 1 agonist DPDPE (middle CTH) in expiratory neurons. The pooled data for both inspiratory and expiratory neurons are shown in figures 3A and B. In inspiratory neurons, peak F n was decreased by DAMGO to 64 ± 4%, by DPDPE to 48 ± 9%, and by deltorphin II to 75 ± 4% of control. The corresponding values for time-averaged F n were: 67 ± 5%, 46 ± 9% and 71 ± 5% of control (Fig. 3B) . In 6 inspiratory neurons naloxone was used and was able to fully reverse the agonist-induced depression.
In expiratory neurons, peak F n was decreased by DAMGO to 68 ± 6%, by DPDPE to 95 ± 3%, and by deltorphin II to 86 ± 4% of control (Fig. 3A, upper) . The corresponding values for time-averaged F n were: 63 ± 8%, 93 ± 3% and 86 ± 4% of control ( Fig. 3B, lower) . Naloxone produced full reversal of all agonist-induced depressions in those expiratory neurons that were tested (n=21).
In a separate protocol, naloxone was picoejected onto 8 inspiratory and 12 expiratory neurons to assess the presence of endogenous opioid receptor activation ( Figure 4 ). Naloxone had no significant effect on inspiratory neurons but produced a
small, yet statistically significant increase of 13 ± 4% in the peak F n and 13 ± 5% in average F n of expiratory neurons.
Picoejection of morphine onto single neurons: assessment of the threshold concentration for a morphine effect and of the maximum morphine effect
In this protocol, 27 bulbospinal neurons (15 inspiratory and 12 expiratory) were studied in 13 animals. The anatomical location of these neurons, based on stereotaxic coordinates, is shown in figure 5 , and is typical for all of the neuron protocols in this report. We used up to three concentrations of morphine in different pipette barrels. The barrel concentrations ranged from 0.01-1.0 mM in order to more precisely delineate the full range of the dose-dependent effects of morphine on neuronal activity. A representative example of the effects of 0.01 mM morphine on an expiratory neuron is shown in figure 6 , which illustrates the approximate lower threshold for morphine induced neuronal depression. At the 0.01 mM morphine barrel concentration, neuronal depression becomes apparent only at the highest picoejection dose rates when the tissue concentration in the vicinity of the neuron is close to the barrel concentration. The peak and average neuronal activity was only minimally depressed at this concentration.
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The pooled data for the depressant effects of maximal dose rates of morphine at each of the three barrel concentrations are shown in figure 7. In inspiratory neurons, peak F n was maximally decreased by 0.01, 0.1 and 1 mM morphine to 82 ± 6%, 75 ± 6% and 62 ± 5% of control (Fig 7A) . The corresponding values for time-averaged F n were: 78 ± 5%, 70 ± 6% and 58 ± 5% of control (Fig. 7B ). For expiratory neurons, peak F n was decreased to 79 ± 3%, 79 ± 5%, and 62 ± 3% of control (Fig. 7A) . The corresponding values for time-averaged F n in expiratory neurons were 82 ± 8%, 76 ± 6% and 58 ± 7% of control (Fig. 7B ). Our sample of expiratory neurons included 6 with an augmenting pattern and 6 with a decrementing pattern. There was no difference between the two types of neurons in the amount of morphine-induced depression of peak F n for the 1 mM concentration (P=0.08, t-test)
The depressant effects of morphine were completely reversed with local application of naloxone in the three neurons that we tested with naloxone in this protocol. Of note, a small number of neurons (n=6), which were analyzed separately, did not show any depression but were excited at the highest morphine concentration.
These neurons were not depressed by morphine but showed a maximum increase in peak F n to 140 ± 9 % of control with 1mM morphine. These excitatory effects could not be reversed with naloxone and thus do not seem to have been opioid receptor mediated.
3.
Picoejection of remifentanil onto single neurons: assessment of a direct depressant effect at clinically relevant concentrations
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Five animals were used for this protocol. Neither of the two remifentanil barrel concentrations (240 and 480 nM) used had a depressant effect on neuronal activity.
We studied 11 inspiratory-and 9 expiratory-neurons respectively and there were no significant differences from control activity. In inspiratory neurons, peak and average F n during picoejection of 480 nM remifentanil solution at maximum dose rates was 96 ± 3%
and 94 ± 4% of control respectively. The corresponding values for expiratory neurons were 95 ± 3% and 101 ± 6% of control, respectively.
Picoejection of the opioid antagonist naloxone onto single neurons during systemic intravenous remifentanil infusion at clinically relevant dose rates
Nine animals were used for this protocol to determine whether opioid receptor activation on premotor neurons contributes to the respiratory neuronal depressant effects of systemic intravenous remifentanil. Figure 8 shows a typical remifentanil protocol. Peak phrenic nerve activity and single neuron activity were depressed by systemic remifentanil infusion by about 50% (Fig. 8a & b) . During steady state infusion naloxone was picoejected onto the neuron to attempt local reversal of the depressant remifentanil effects (Fig. 8c) . Since neuronal activity did not increase with maximal local naloxone rates, direct neuronal postsynaptic opioid receptor activation did not appear to contribute to the depression of neuronal activity. Pooled data show that systemic infusions of remifentanil depressed phrenic nerve activity by about 50% and decreased the peak inspiratory and expiratory premotor neuron discharge frequency to 60 ± 4%
(n=7) and 58 ± 3% (n=11), respectively (see figure 9 ). Local naloxone ejection did not reverse any of the remifentanil-induced neuronal depression (peak F n of inspiratory and 17 expiratory neurons: 62 ± 4% and 56 ± 3%, respectively; Fig. 9 REMI & Naloxone).
These data confirm that clinically relevant infusions of remifentanil do not depress respiratory premotor neurons via postsynaptic opioid receptor activation on these neurons, but rather via upstream effects. After discontinuation of the remifentanil infusion, inspiratory neuronal activity recovered to baseline. Control ejection of naloxone had no effect on inspiratory neurons. However, expiratory neuronal activity showed a small but significant increase in F n compared to control (Fig. 9 , End Control & Naloxone).
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DISCUSSION
The main findings of these studies show that opioid receptor activation on functionally well-defined bulbospinal respiratory neurons in an in vivo canine preparation depresses neuronal activity, but that neuronal depression with morphine occurs only at local concentrations above the clinical range. In addition, clinical doses of intravenous remifentanil, which depress the activity of these neurons to a similar extent as maximally effective local agonist concentrations, do not act via direct opioid receptor activation. Thus, opioid-induced effects on presynaptic neurons appear to be responsible for the depression of these neurons at clinical concentrations.
Inspiratory premotor neurons respond to µ, δ1 and δ2 opioid receptor activation while expiratory neurons only respond to µ and δ2 activation.
We found that both µ and δ agonists depressed the activity of respiratory premotor neurons, but that the δ 1 receptor agonist DPDPE was ineffective for expiratory neurons, yet highly effective for inspiratory neurons. Local antagonism with the nonselective antagonist naloxone fully reversed any depressant opioid effects. These results match radioactive labeling studies that show µ-as well as δ opioid receptors distributed in the respiratory centers of the brainstem (Sales et al. 1985) . Haji et al.
(2003b) showed with immunoreactive labeling that µ receptors were widely distributed on functionally identified bulbospinal respiratory neurons. Our study provides additional evidence that δ  receptor activation can contribute to depression of respiratory neurons, and it is the first to demonstrate a depression of functionally identified respiratory premotor neurons by δ agonists. Interestingly, there was a ceiling effect of 40-50% depression for all agonists and even maximally effective agonist dose rates were not able to completely silence any of these neurons. Indeed, many neurons were only moderately depressed, i.e., much less than 50% at maximally effective local agonist dose rates.
Only supraclinical doses of morphine have a direct depressant effect on respiratory premotor neurons
The µ receptor agonist morphine has been shown to depress respiratory neurons in vivo. Using iontophoresed morphine (50 mM) onto single bulbar respiratory neurons in spinalized cats, Denavit-Saubie et al. (1978) found that 35 of 58 neurons were dosedependently depressed while 14 showed no effect, and 9 showed dose dependent excitation that, unlike the depressive effects, was not naloxone-reversible. 
Clinically relevant concentrations of remifentanil do not have a direct depressant effect on respiratory premotor neurons
We used two barrel concentrations of remifentanil (240 and 480 nM), which were 20 and 40 times higher than the peak plasma concentration reached during intravenous infusions at high clinical dose rates. At the steady-state picoejection rates that were 21 used, the drug concentration within 100-200 µm of the pipette tip will eventually approach the barrel concentration. To obtain adequate signal strength, the neuron is typically less than 100 µm from the tip, so we are fairly confident that our neuronal remifentanil target concentrations during picoejection exceeded peak plasma concentrations during intravenous remifentanil by at least 20 fold. Due to the presence of glycine in the remifentanil product, we did not test higher remifentanil concentrations to avoid the confounding effects of glycine-mediated inhibition. The glycine concentrations corresponding to the 240 nM and 480 nM remifentanil concentrations were 10 µM and 20 µM, respectively. We have shown that glycine concentrations in the range of 0.5-1 mM produce a marked inhibition of respiratory neuronal activity, including premotor neurons. Neither of the two remifentanil/glycine concentrations had an appreciable effect on premotor neuronal activity. These data suggested that remifentanil at clinically relevant concentrations does not directly depress respiratory bulbospinal neurons, which was confirmed by the systemic remifentanil protocol.
Intravenous remifentanil depresses respiratory premotor neuron activity but not through direct neuronal opioid receptor activation
We explored the effects of clinical plasma concentrations further by using an infusion of the ultra-short acting µ agonist remifentanil, which allowed steady state depression of neuronal activity as well as end controls without residual opioid activity.
The results show that remifentanil at clinically relevant infusion rates, which caused significant depression of phrenic nerve activity (~50%), also significantly depressed respiratory premotor neuron activity (~40%). We conclude that none of this depression is due to the direct action of the opioid on inspiratory and expiratory bulbospinal neurons 22 due to the evidence from our two approaches. 1) During intravenous remifentanil the difference in neuronal peak discharge frequency immediately before and during picoejection of naloxone was less than 1% (mean±SD: 0.86±6.5%, paired t-analysis; P=0.579) for 18 neurons. 2) Picoejection of remifentanil at concentrations 20-40 times greater than the expected peak plasma concentration during intravenous infusions at high clinical dose rates did not alter the discharge frequency of these neurons. In addition, the sensitivity of our technique was able to detect a 13% increase in expiratory neuronal activity produced by local picoejection of naloxone indicating a small but significant level of endogenous opioidergic activity. Thus, we conclude that intravenous remifentanil had no direct effect on the respiratory bulbospinal neurons, and that their depression was due to presynaptic effects.
We believe that the discrepancy between the direct, reversible depressant effect of morphine on single neurons that we and other investigators observed, and the lack of local naloxone reversibility of the intravenous remifentanil results from the difference of the attained agonist concentrations at the neuronal level. The remifentanil infusion rates we used (≈0.5 µg/kg/min) are expected to result in plasma concentrations of ≤ 10 ng/ml or ≤ 24 nanomolar (Michelsen et al. 1996) in dogs, which is ≈ 40,000 times less than the maximal concentrations of DAMGO or morphine that were used in the local picoejection experiments to cause a similar depression of neuronal activity.
Furthermore, picoejected remifentanil at concentrations >20 times larger than reported peak plasma concentrations during systemic remifentanil infusions had no effect on the discharge frequency of the bulbospinal neurons. Taken together our data strongly suggest that clinical doses of therapeutic µ opioid agonists depress respiratory premotor 23 neurons by affecting mechanisms upstream from these neurons and not via direct opioid receptor activation on these neurons.
With regard to the nature of the presynaptic depression by intravenously administered opioids at clinical doses, our experimental approach is unable to pinpoint the exact mechanism. However, we speculate that the remifentanil-induced depression of the bulbospinal premotor neurons by ~40% is likely due to effects on specific presynaptic neurons that are extremely sensitive to the opioid at clinical concentrations.
An alternative explanation is that the opioid is producing a small amount of postsynaptic depression throughout the network and the summation of these small effects produces the 40% depression of the bulbospinal neurons. In order for this latter explanation to be true, it would require these small effects to be propagated in a cascade manner in order -Schild et al. 1999) suggests that the pontine input to bulbospinal neurons is also depressed.
Another potential source of opioid-induced presynaptic depression are neurons within the preBötzinger complex (preBC). In a neonatal rat preparation, Gray et al. (1999) suggested that the distribution of Neurokinin-1 (NK1) receptor neurons anatomically defined the preBC and that a subpopulation of neurons expressing both NK1 receptors and µ opioid receptors generate respiratory rhythm and modulate respiratory frequency. Furthermore, NK1 receptor-expressing cells within the preBC are predominantly glutamatergic (Guyenet et al. 2002) . Correlation analysis between rostral and caudal VRG inspiratory neurons suggests that the more rostral pBC neurons drive the more caudal bulbospinal neurons (Rekling and Feldman 1998; Segers et al. 1987 ).
Thus, any opioid-induced depression of preBC neurons may reduce excitatory drive to the bulbospinal neurons.
Methodological Considerations
This is the first study to use a continuous infusion of remifentanil to test for opioid effects on respiratory neurons in vivo. The establishment of a clinically relevant steadystate opioid concentration, as judged from the steady-state ≈50% depression of phrenic nerve activity, is important to achieve conclusive results. 
Lack of endogenous opioid activity at the premotor neuronal level
In our preparation naloxone did not have any effect on inspiratory neuron activity indicating that no endogenous opioid activation was present. However, a small but statistically significant increase in neuronal frequency by ~10% was observed in expiratory neurons in both, substudies 2 and 3. Haji also described small excitatory effects of iontophoresed naloxone due to membrane depolarization in 5 of 18 bulbar respiratory neurons in decerebrate cats (Haji et al. 2003a ). However, the systemic administration of large doses of naloxone (0.1 mg/kg) did not alter resting ventilation in healthy human volunteers (Bianchi et al. 1995; Tabona et al. 1982) . The physiological role of opioidergic/ enkephalinergic inputs on the respiratory system has yet to be clarified.
In conclusion, our current studies on bulbospinal respiratory premotor neurons in decerebrate dogs provide evidence that these neurons express functional µ and δ opioid receptors. However, clinically relevant concentrations of the µ agonist remifentanil that depress phrenic nerve activity and respiratory premotor neuron activity by ≈ 50% appear to exert their effects entirely upstream from these premotor neurons,
i.e., at presynaptic neurons.
Legends:
Figure 1
Response of an inspiratory premotor neuron to the selective µagonist DAMGO: A: The extracellularly recorded activity of the neuron was dose-dependently depressed by 1 mM DAMGO which was ejected at increasing dose rates onto the neuron until maximal effects were reached at the peak dose rate of 67 pmol/min. DAMGO application was highly localized and phrenic nerve activity (PNG) was not affected. B: time-expanded views of the neuron activity during control and at maximum DAMGO effect. Note that the neuron discharged in phase with the phrenic nerve and was thus an inspiratory neuron. PNG: time averaged phrenic neurogram (arbitrary units), Marker: picoejection marker, F n : neuronal rate-meter recording of the action potential discharge frequency in Hz, NA: extracellular neuron activity. Pooled data for the depressant effects of three selective opioid agonists at maximally effective dose-rates and naloxone reversal on neuron activity, normalized to preejection control: A: Effect on peak discharge frequency. B: Effect on average discharge frequency. # indicates significant difference compared to control (100%) and * indicates significant difference between type of neuron (# p < 0.05, ## p < 0.01, ### p < 0.001, * p < 0.05, ** p < 0.01, *** p < 0.001).
Figure 4
Pooled data of the effect of the non-selective opioid antagonist naloxone on control neuron activity at maximally effective dose-rates: In this protocol naloxone was given to assess any endogenous opioid effects on premotor neurons that may be present during the control condition. Left: Effect on peak discharge frequency. Right: Effect on average discharge frequency. Data (mean & SE) were normalized to pre-ejection control values.
Naloxone caused a small but statistically significant excitation in expiratory neurons (see text for details). The # indicates significant difference compared to control (# p < 0.05, ## p < 0.01). Pooled data for the effects of three concentrations of morphine at maximally effective dose-rates on neuron activity, normalized to control (100%). A: Effect on peak discharge frequency. B: Effect on average discharge frequency. # indicates significant difference compared to control (# p < 0.05, ## p < 0.01, ### p < 0.001). Increasing concentrations of morphine caused a dose-dependent depression of respiratory premotor neurons but there was no statistically significant difference between the two neuron types. extracellularly recorded neuronal activity and the peak phrenic nerve activity during control conditions (a) and at ≈50% depression by the systemic remifentanil infusion (b).
During continuous remifentanil infusion (b) the opioid antagonist naloxone was picoejected directly onto the neuron (c). Despite high naloxone dose rates, which had previously been shown to fully reverse the depressant effects of a locally applied µ agonist (DAMGO), the remifentanil induced neuronal depression was not reversed.
After termination of remifentanil neuronal discharge activity recovered to control levels 
